Inner Ear Drug Delivery: a case study on the Inner Ear Delivery of Neurotrophin-3
10 September 2019 13:50 - 14:25
Overview of the inner ear drug delivery
A case study on the inner ear delivery of NT3, including (1) The electrophysiological response after dosing NT3 in a noise induced hearing loss mouse model; (2) The NT3 disposition in the perilymph; (3) The NT3 distribution in the cochlear tissue determined by radio-imaging methods; (4) The pharmacodynamic response in cochlea upon the inner ear dosing of NT3.
Qi-Ying Hu is the Director of Formulation and Drug Delivery at Decibel Therapeutics, where he spearheads the establishment of the otic drug delivery platform and the discovery of clinical candidates in the diverse therapeutic modality space. Prior to his current role, Dr. Hu served as a labhead and project team leader at the Novartis Institute for BioMedical Research (NIBR), where he led multiple drug discovery programs and technology platforms in various disease areas. His efforts led to the discovery of several clinical candidates, such as Osilodrostat (phase 3), and the establishment of platforms, including site-specific ADCs, long acting biologics, well-defined vaccines, and local (e.g. eye and ear) drug delivery systems. Dr. Hu has a strong technology background with over 15 years’ experience in the biopharmaceutical industry within drug discovery and development in broad therapeutic areas. He received his PhD in organic chemistry at National University of Singapore in 2001, and was a postdoctoral fellow with Professor E. J. Corey at the Harvard University from 2002 to 2004. Dr. Hu is a co-inventor for 20+ patents, and a co-author for 20+ scientific publications. He serves as a reviewer for several scientific journals. He is also a co-chair for the Massbio forum in his spare time.